Candel Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Candel Therapeutics R&D Spending Growth & History (CADL)
Candel Therapeutics's r&d spending was $30.5M for fiscal 2025.
View full Candel Therapeutics company overviewCandel Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $30.5M | $11.2M | +57.90% |
| 2024 | 2024-12-31 | $19.3M | −$5.2M | −21.19% |
| 2023 | 2023-12-31 | $24.5M | $3.7M | +17.89% |
| 2022 | 2022-12-31 | $20.8M | $5.6M | +36.95% |
| 2021 | 2021-12-31 | $15.2M | $6.4M | +73.38% |
| 2020 | 2020-12-31 | $8.8M | — | — |
Candel Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.8M | $12.8M | +183.24% |
| Q1 2026 | 2026-03-31 | $9.8M | $5.8M | +145.02% |
| Q4 2025 | 2025-12-31 | $11.0M | $6.2M | +128.94% |
| Q3 2025 | 2025-09-30 | $8.5M | $3.0M | +56.22% |
| Q2 2025 | 2025-06-30 | $7.0M | $2.0M | +40.41% |
| Q1 2025 | 2025-03-31 | $4.0M | −$86,000 | −2.10% |
| Q4 2024 | 2024-12-31 | $4.8M | −$2.4M | −33.63% |
| Q3 2024 | 2024-09-30 | $5.4M | −$429,000 | −7.34% |
| Q2 2024 | 2024-06-30 | $5.0M | −$955,000 | −16.09% |
| Q1 2024 | 2024-03-31 | $4.1M | −$1.4M | −25.00% |
| Q4 2023 | 2023-12-31 | $7.3M | $2.3M | +45.98% |
| Q3 2023 | 2023-09-30 | $5.8M | $469,000 | +8.72% |
| Q2 2023 | 2023-06-30 | $5.9M | $912,000 | +18.16% |
| Q1 2023 | 2023-03-31 | $5.5M | $52,000 | +0.96% |
| Q4 2022 | 2022-12-31 | $5.0M | $1.1M | +28.54% |
| Q3 2022 | 2022-09-30 | $5.4M | $111,000 | +2.11% |
| Q2 2022 | 2022-06-30 | $5.0M | $1.7M | +52.55% |
| Q1 2022 | 2022-03-31 | $5.4M | $2.7M | +96.77% |
| Q4 2021 | 2021-12-31 | $3.9M | — | — |
| Q3 2021 | 2021-09-30 | $5.3M | $3.5M | +190.40% |
| Q2 2021 | 2021-06-30 | $3.3M | $1.5M | +83.40% |
| Q1 2021 | 2021-03-31 | $2.8M | — | — |
| Q3 2020 | 2020-09-30 | $1.8M | — | — |
| Q2 2020 | 2020-06-30 | $1.8M | — | — |
Candel Therapeutics r&d spending trends
Over the last five fiscal years, Candel Therapeutics's r&d spending increased from $8.8M to $30.5M, a change of $21.7M. The latest reported quarter, Q2 2026, shows $19.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Candel Therapeutics source filings ↗